JK-05
JK-05
JK-05 (pronounced: J-K-Zero-Five) is a pharmaceutical drug developed by the China-based company, Sihuan Pharmaceutical Holdings Group Ltd.. It is primarily used as an experimental treatment for the deadly Ebola virus.
Etymology
The name "JK-05" is derived from the initials of the lead scientist, Dr. Jiankui, who was instrumental in the development of the drug, and the number "05" represents the fifth iteration of the drug that was deemed successful for further testing and development.
Usage
JK-05 is used as a potential treatment for the Ebola virus. The drug works by inhibiting the replication of the virus in the body, thereby reducing the severity of the disease. It is currently in the experimental stage and is not yet widely available for use.
Related Terms
- Ebola virus: A severe, often fatal illness in humans. The virus is transmitted to people from wild animals and spreads in the human population through human-to-human transmission.
- Sihuan Pharmaceutical Holdings Group Ltd.: A China-based pharmaceutical company that developed JK-05.
- Pharmaceutical drug: A drug used to diagnose, cure, treat, or prevent disease.
- Virus replication: The process by which a virus makes copies of itself within a host organism.
See Also
External links
- Medical encyclopedia article on JK-05
- Wikipedia's article - JK-05
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski